The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models.

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • F Handle - (Author)
  • M Puhr - (Author)
  • G Schaefer - (Author)
  • N Lorito - (Author)
  • J Hoefer - (Author)
  • M Gruber - (Author)
  • F Guggenberger - (Author)
  • FR Santer - (Author)
  • RB Marques - (Author)
  • Weerden WM van - (Author)
  • F Claessens - (Author)
  • HHH Erb - , Department of Urology (Author)
  • Z Culig - (Author)

Details

Original languageEnglish
JournalMolecular cancer therapeutics
Publication statusPublished - Sept 2018
Peer-reviewedYes

External IDs

PubMed 30254184
Scopus 85057586727

Keywords